达罗他胺在按前列腺特异性抗原倍增时间分层的非转移性去势抵抗性前列腺癌患者中的疗效与安全性:3期ARAMIS试验的计划亚组分析
这项3期ARAMIS试验的计划亚组分析纳入1509例非转移性去势抵抗性前列腺癌且PSADT≤10个月的患者,随机2:1接受达罗他胺600mg每日两次或安慰剂。PSADT>6个月亚组中达罗他胺显著延长无转移生存(HR 0.38),PSADT≤6个月亚组同样显著(HR 0.41),总生存和生活质量等终点均 favoring 达罗他胺,不良事件发生率低且与安慰剂相似。
要点
- PSADT>6个月亚组达罗他胺显著延长无转移生存(HR 0.38,95%CI 0.26-0.55)。
- PSADT≤6个月亚组达罗他胺同样显著延长无转移生存(HR 0.41,95%CI 0.33-0.52)。
- 两个亚组总生存、生活质量等终点均 favoring 达罗他胺,不良事件发生率低且与安慰剂相似。
核心结论
- 在PSADT>6个月(最长10个月)的非转移性去势抵抗性前列腺癌患者中,达罗他胺提供有利的获益/风险比,表现为无转移生存、总生存及其他临床相关终点的显著改善、生活质量维持和良好的耐受性。
研究设计与样本
- 全球多中心、双盲、随机3期试验的计划亚组分析,纳入非转移性去势抵抗性前列腺癌且PSADT≤10个月的男性患者。
- 共入组1509例患者,按2:1随机接受口服达罗他胺600mg每日两次或安慰剂,同时继续雄激素剥夺治疗。
- PSADT>6个月亚组469例(达罗他胺n=286;安慰剂n=183),PSADT≤6个月亚组1040例(达罗他胺n=669;安慰剂n=371)。
主要发现
- 达罗他胺在PSADT>6个月亚组显著延长无转移生存(未分层HR 0.38,95%CI 0.26-0.55),在PSADT≤6个月亚组同样显著(未分层HR 0.41,95%CI 0.33-0.52)。
- 两个亚组中总生存及其他疗效和生活质量终点均 favoring 达罗他胺,较安慰剂有显著改善。
- 不良事件(包括骨折、跌倒、高血压和精神损害等与雄激素受体抑制剂常见相关的事件)发生率低,因不良事件停药率低,且与安慰剂相似。
局限性
- 局限性包括亚组人群样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a high risk of progression to metastatic disease, particularly if their prostate-specific antigen doubling time (PSADT) is ≤6 mo. However, patients remain at a high risk with a PSADT of >6 mo. OBJECTIVE: To evaluate the efficacy and safety of darolutamide versus placebo in patients stratified by PSADT >6 or ≤6 mo. DESIGN, SETTING, AND PARTICIPANTS: A planned subgroup analysis of a global multicenter, double-blind, randomized, phase 3 trial in men with nmCRPC and PSADT ≤10 mo was conducted. INTERVENTION: Patients were randomized 2:1 to oral darolutamide 600 mg twice daily or placebo, while continuing androgen-deprivation therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was metastasis-free survival (MFS). Secondary endpoints were overall survival (OS) and times to pain progression, first cytotoxic chemotherapy, and symptomatic skeletal events. Quality of life (QoL) was measured using validated prostate-relevant tools. Safety was recorded throughout the study. RESULTS AND LIMITATIONS: Of 1509 patients enrolled, 469 had PSADT >6 mo (darolutamide n = 286; placebo n = 183) and 1040 had PSADT ≤6 mo (darolutamide n = 669; placebo n = 371). Baseline characteristics were balanced between subgroups. Darolutamide significantly prolonged MFS versus placebo in both subgroups (unstratified hazard ratio [95% confidence interval]: PSADT >6 mo, 0.38 [0.26-0.55]; PSADT ≤6 mo, 0.41 [0.33-0.52]). OS and other efficacy and QoL endpoints favored darolutamide with significant improvement over placebo in both subgroups. The incidence of adverse events, including events commonly associated with androgen receptor inhibitors (fractures, falls, hypertension, and mental impairment), and discontinuations due to adverse events were low and similar to placebo. Limitations include small subgroup populations. CONCLUSIONS: In patients with nmCRPC and PSADT >6 mo (maximum 10 mo), darolutamide provided a favorable benefit/risk ratio, characterized by significant improvements in MFS, OS, and other clinically relevant endpoints; maintenance of QoL; and favorable tolerability. PATIENT SUMMARY: In patients with prostate cancer that has stopped responding to standard hormonal therapy (indicated by an increase in prostate-specific antigen [PSA] levels), there is a risk that the cancer will spread to other parts of the body. This risk is highest when the time it takes for the PSA level to double (ie, "PSA doubling time" [PSADT]) is less than 6 mo. However, there is still a risk that the cancer will spread even if the PSADT is longer than 6 mo. In a group of patients whose PSADT was more than 6 mo but no more than 10 mo, treatment with darolutamide slowed the cancer spread and allowed them to live longer than patients who received placebo (inactive drug). Darolutamide treatment did not cause many side effects and helped maintain patients' quality of life without disruptions.
引用
- Bögemann M, Shore ND, Smith MR, et al. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Eur Urol. 2022. PMID: 36089529. doi:10.1016/j.eururo.2022.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。